Novavax, Inc. (NASDAQ:NVAX)

CAPS Rating: 1 out of 5

A biopharmaceutical company focused on creating differentiated, value-added vaccines that improve upon current preventive options for a range of infectious diseases.

Recs

0
Player Avatar BuffettJunior1 (97.53) Submitted: 4/30/2011 7:30:04 PM : Underperform Start Price: $2.50 NVAX Score: +45.57

Perfect short candidate!

Featured Broker Partners


Advertisement